Third Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INC

Financial Performance:

• Third quarter 2026 revenue reached $13.2 million, up from $7.6 million in the prior year period, driven by the ongoing collaboration with GSK.
• Research and development expenses were $53.8 million, an increase from $45.9 million year-over-year, reflecting investment in advancing clinical programs including Phase 2a InLight and the RNA editing pipeline.
• General and administrative expenses rose to $25.4 million from $18.1 million, due to pipeline advancement costs and preparations for future development stages.
• Net loss for the quarter was $61.9 million compared to $53.9 million in the prior year quarter.
• The company ended the quarter with $431 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into Q3 2028.
• An incremental $12 million milestone payment is expected from GSK in Q4 2026 following the selection of a development candidate.

Guidance and Future Outlook:

• WVE-007 Phase 2a monotherapy data is expected to demonstrate meaningful body composition changes, with a goal of crossing the 12-month regulatory threshold of 5% weight loss.
• Upcoming data releases in Q4 include 600 mg results from the Phase 1 single ascending dose (MAD) portion of the InLight trial to characterize potency and durability.
• WVE-006 (RNA editing for AATD) is on track for a single registrational trial design aimed at full approval, potentially with an interim analysis for accelerated approval based on biomarkers at one year.
• WVE-008 (RNA editing for PNPLA3 liver disease) remains on track for a Clinical Trial Application (CTA) submission in 2026.
• A Phase 2a post-incretin maintenance trial for WVE-007 is scheduled to initiate in Q4 2026.
• WVE-007 combination trial with trisepatide (GLP-1) initiated in Q3 2026.

Business Segments and Product Lines:

• Obesity (WVE-007): An inhibin-E siRNA targeting visceral and subcutaneous fat loss while preserving lean mass; distinct mechanism from incretin-based therapies.
  • Currently evaluating three settings: monotherapy (Phase 2a), combination therapy with trisepatide (Phase 2a), and post-incretin maintenance.
  • Preclinical data shows substantial fat loss with muscle preservation; Phase 1 data shows durable, dose-dependent activity supporting once or twice-yearly dosing.
• AATD (WVE-006): An RNA editing candidate treating both lung and liver manifestations by restoring a dynamic MZ-like phenotype; following a positive FDA meeting, a single two-year pivotal trial is planned.
• Liver Disease (WVE-008): An RNA editing candidate targeting PNPLA3 I148M to restore wild-type protein function, distinct from silencing approaches.
• Collaboration: GSK selected an additional siRNA development candidate from WAVE's SPINA platform to transition into GSK's pipeline, validating the platform's capabilities.

Market and Competitive Landscape:

• Obesity: Positioning WVE-007 as an alternative to GLP-1s by addressing muscle loss (up to 40% of weight lost with current therapies) and high discontinuation rates; potential to enable weight maintenance and reduce fat regain post-cessation.
• AATD: Differentiating from IV augmentation (which lacks liver impact and dynamic response) and DNA editing (safety concerns, one-time cost, permanence) by offering a reversible, dynamic, subcutaneous therapy.
• Platform Validation: Recent Nobel Prize in Chemistry for stereochemistry validates the importance of chirality in WAVE's proprietary chemistry; the company's ability to optimize chiral mixtures is a key competitive differentiator.
• Regulatory Environment: FDA indicated support for RNA editing approaches in rare diseases and is open to using validated LC-MS assays for AATD biomarkers, avoiding the need for redefining non-native proteins.

Risks and Challenges:

• Regulatory Pathways: While a single trial design is supported for WVE-006, specific endpoints for full vs. accelerated approval remain to be finalized; reliance on surrogate biomarkers (MZ-like phenotype) requires sustained validation.
• Market Adoption: Uncertainty regarding the specific magnitude of weight loss required for commercial viability in the obesity space versus the 5% regulatory bar.
• Competitive Landscape: Rapid advancements in the obesity space (GLP-1s) and the rare disease sector (other siRNA/RNA editing candidates from Arrowhead, Takeda, etc.) present competition for patient enrollment and market share.
• Execution Risks: Maintaining clinical trial enrollment timelines, particularly for rare diseases, and successfully transitioning complex RNA editing molecules from discovery to registration.

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing "strong execution," "compelling data," and "differentiated" mechanisms.
• Management expressed excitement over FDA alignment on WVE-006's efficient trial design, viewing it as a departure from the standard confirmatory trial requirements seen in other gene editing programs.
• New Chief Business Officer, Monica Vinuk, emphasized her immediate focus on leveraging the platform for strategic partnerships and expanding the pipeline.
• Leadership highlighted the strategic value of the WAVE platform (SPINA design) and the GSK collaboration as evidence of industry validation.

Analyst Questions and Answers:

• WVE-006 Trial Design: Confirmed that the single trial design aims for full approval without a separate confirmatory study; interim analysis at one year based on MZ-like phenotype (increased M >50%, decreased Z, acute phase response) for accelerated approval.
• WVE-007 Efficacy: Management reaffirmed confidence in reaching the 5% weight loss threshold in the Phase 2a population due to higher baseline adiposity; emphasized that fat loss preservation of muscle is the key differentiator.
• Combination Therapy: WVE-007 with trisepatide aims to deepen weight loss and mitigate muscle loss; additive benefit expected without needing a separate regulatory approval if the monotherapy meets its bar.
• WVE-007 Dosing: 600 mg data will help optimize dosing frequency; maintenance doses may differ (potentially lower) than induction doses for weight loss.
• GSK Partnership: The relationship is described as mutually beneficial and aligned; GSK's recent selection of a candidate validates the platform's ability to unlock diverse targets.
• EU Regulations: EU acceptance of CT densitometry as a primary endpoint may facilitate a rapid path to approval in Europe for WVE-006.
• Body Composition: Management noted a shift in regulatory and clinical focus from total weight loss to body composition (visceral fat reduction, lean mass preservation), which WVE-007 directly addresses.

Other Key Points:

• WAVE is hosting its annual Research Day next week to present deeper data on the SPINA platform, hepatic/extrahepatic siRNA, RNA editing, and bifunctional modalities.
• Dr. Arun Sanyal, a leading hepatologist, will join the Research Day to discuss PNPLA3 liver disease.
• The company has engaged with patient advocacy groups for AATD (Alpha-1) to leverage registries for accelerated enrollment.
• WAVE's approach to WVE-006 avoids "bystander editing" risks associated with DNA editing and "permanent" genomic modifications, positioning it as a safer, reversible alternative.
• The company is preparing to present data at Obesity Week to engage key opinion leaders on the obesity program.